Nephros Revenue and Competitors
Estimated Revenue & Valuation
- Nephros's estimated annual revenue is currently $7.5M per year.
- Nephros's estimated revenue per employee is $156,250
- Nephros's total funding is $11.2M.
Employee Data
- Nephros has 48 Employees.
- Nephros grew their employee count by 9% last year.
Nephros's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Research & Development | Reveal Email/Phone |
2 | Controller | Reveal Email/Phone |
3 | VP, Quality, Regulatory and Human Resources | Reveal Email/Phone |
4 | Director Dialysis Products | Reveal Email/Phone |
5 | Director Logistics and Manufacturing | Reveal Email/Phone |
6 | Director, Revenue Operations | Reveal Email/Phone |
7 | Director Brand, Marketing, & Business Development | Reveal Email/Phone |
8 | Chief Commercial Officer (CCO) | Reveal Email/Phone |
9 | Associate Director - Northeast | Reveal Email/Phone |
10 | Chief Financial Officer | Reveal Email/Phone |
Nephros Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $7.8M | 31 | 11% | N/A | N/A |
#2 | $12.3M | 49 | -4% | N/A | N/A |
#3 | $15.1M | 60 | 7% | N/A | N/A |
#4 | $8.8M | 35 | -8% | N/A | N/A |
#5 | $3M | 12 | 9% | N/A | N/A |
#6 | $300.4M | 1197 | 3% | N/A | N/A |
#7 | $311.7M | 1242 | 2% | N/A | N/A |
#8 | $0.3M | 1 | -96% | N/A | N/A |
#9 | $8.3M | 33 | 3% | N/A | N/A |
#10 | $13.6M | 54 | 8% | N/A | N/A |
What Is Nephros?
Nephros, Inc. was founded in 1997 by Columbia University health professionals, scientists and engineers to improve the quality of life for the End Stage Renal Disease (ESRD) patient, while addressing the critical needs of the care provider. The Company has developed the most effective ESRD therapy available worldwide, offering unique and proprietary technologies that dramatically improve clinical efficacy. Nephros technologies also remove a range of harmful substances not currently removed by existing dialysis methods; addressed specifically are substances known collectively as middle molecules, due to their molecular weight, that contribute to such conditions as carpal tunnel syndrome, dialysis related amyloidosis, and degenerative bone disease in the ESRD patient.
keywords:N/A
$11.2M
Total Funding
48
Number of Employees
$7.5M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Nephros News
Nephros has set its FY 2022 guidance at EPS. Nephros (NASDAQ:NEPH Get Rating) last posted its quarterly earnings results on Wednesday,...
According to Zacks, Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient...
SOUTH ORANGE, NJ, April 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc.(Nasdaq: NEPH), a leading water technology company...
Other Companies in South Orange
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $10M | 62 | 0% | N/A |
#2 | $15.8M | 65 | 10% | N/A |
#3 | $3.5M | 66 | 2% | N/A |
#4 | $15.8M | 77 | 3% | N/A |
#5 | $20M | 80 | 1% | N/A |